Recent Company News

• 06:19 AM ET Aug 21, 2026
  

  NMPA approves trial of Sino Biopharmaceutical unit Chia Tai Tianqing's TQF6422 for overweight or obesity (HK$5.60, 0.00)

• 11:21 PM ET Aug 19, 2026
  

  Quick Take - Sino Biopharmaceutical trading +17.5% post H1 beat; strength in innovative portfolio, AI led cost efficiencies cited (HK$5.58, +0.78)

• 11:11 PM ET Aug 19, 2026
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:43 PM ET Aug 19, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 04:54 AM ET Aug 19, 2026
  

  StreetAccount Metrics Recap - Sino Biopharmaceutical H1 Earnings (HK$4.79, 0.00)

• 04:39 AM ET Aug 19, 2026
  

  Sino Biopharmaceutical reports H1 underlying profit CNY3.34B, +8% vs year-ago CNY3.09B (HK$4.79, 0.00)

• 07:09 AM ET Aug 07, 2026
  

  NMPA approves Sino Biopharma's benmelstobart combination as first-line treatment of sq-NSCLC (HK$5.10, 0.00)

• 05:42 AM ET Aug 06, 2026
  

  Sino Biopharmaceutical receives NMPA marketing approval for second-generation flurbiprofen patch (HK$4.93, 0.00)

• 12:11 AM ET Aug 06, 2026
  

  StreetAccount Sector Summary - China Healthcare July Recap

• 04:54 AM ET Aug 04, 2026
  

  Sino Biopharmaceutical receives NMPA acceptance of new drug application for TQB3909 tablet (HK$4.95, 0.00)